Morning Movers 08/10: (FIO) (EPAY) (XIN) Higher; (UBNT) (RNDY) (IMPV) Lower
Tweet
Share
E-mail
Get Alerts UBNT Hot Sheet
Join SI Premium – FREE
Ubiquiti Networks (Nasdaq: UBNT) 42.7% LOWER; reported Q4 EPS of $0.30, $0.01 better than the analyst estimate of $0.29. Revenue for the quarter came in at $94.9 million versus the consensus estimate of $94.59 million. Sees Q1 2013 EPS of $0.14-$0.17, versus the consensus of $0.29. Sees Q1 2013 revenue of $62-$70 million, versus the consensus of $98.4 million. Downgraded at Wedbush, Deutsche Bank, Capstone, and Pacific Crest today.
Fusion-io (NYSE: FIO) 28.7% HIGHER; reported Q4 EPS of $0.09, versus $0.15 reported last year. Revenue for the quarter came in at $106.6 million, versus $71.7 million reported last year. Sees Q113 revs up modestly from Q4. Sees FY13 revenue growth in the range of 45 to 50%. For more, click here.
Roundys (NYSE: RNDY) 24.2% LOWER; reported Q2 EPS of $0.42, $0.01 worse than the analyst estimate of $0.43. Revenue for the quarter came in at $996.8 million versus the consensus estimate of $998.13 million. Sees FY2012 EPS of $1.10-$1.24, versus the consensus of $1.34. Downgraded by BB&T, Jefferies, and Credit Suisse.
Bottomline Technologies, Inc. (Nasdaq: EPAY) 20.8% HIGHER; reported Q4 EPS of $0.26, $0.04 better than the analyst estimate of $0.22. Revenue for the quarter came in at $61.4 million versus the consensus estimate of $59.75 million.
Imperva, Inc. (NYSE: IMPV) reported Q2 EPS of ($0.02), $0.03 better than the analyst estimate of ($0.05). Revenue for the quarter came in at $24.6 million versus the consensus estimate of $23.6 million. Sees Q3 2012 revenue of $24.6-$25 million, versus the consensus of $24.7 million. Imperva also sees FY2012 revenue of $99.5-$101.5 million, versus the consensus of $99.1 million.
Codexis, Inc. (Nasdaq: CDXS) 16.8% LOWER; reported Q2 EPS of ($0.15), $0.04 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $22.9 million versus the consensus estimate of $29.84 million.
Xinyuan Real Estate Co. (NYSE: XIN) 16.6% HIGHER; reported Q2 EPS of $0.94, $0.54 better than the analyst estimate of $0.40. Revenue for the quarter came in at $253.1 million versus the consensus estimate of $213.3 million. Sees Q3 2012 revenue of $225-$235 million, versus the consensus of $201.20 million. Sees FY2012 revenue of $825-$845 million, versus the consensus of $771.30 million. Yesterday, August 9, 2012, the Company acquired a parcel of land In Suzhou with a total GFA of approximately 128,000 square meters at a cost of RMB270 million(US$42.6 million).
eMagin Corp. (NYSE: EMAN) 15.3% HIGHER; reported Q2 EPS of $0.02, versus $0.01 reported last year. Revenue for the quarter came in at $8.6 million versus the consensus estimate of $7.4 million.
PharmAthene, Inc. (AMEX: PIP), 14.4% LOWER; received notification from the U.S. Food and Drug Administration (FDA) that its SparVax rPA anthrax vaccine program has been placed on clinical hold. The Agency indicated that the Company will receive a letter providing details of the basis for the clinical hold within 30 days. During this period, PharmAthene will continue to provide the agency with analytical data from its recently produced GMP lot of material. The clinical study, which was expected to begin by the end of this year, has not enrolled any subjects to date and accordingly, there have been no adverse events reported.
51job Inc (Nasdaq: JOBS) 13.1% HIGHER; reported Q2 EPS of $0.66, $0.09 better than the analyst estimate of $0.57. Revenue for the quarter came in at $56.7 million versus the consensus estimate of $55.4 million.
DG FastChannel, Inc. (Nasdaq: DGIT) 13.0% LOWER; reported Q2 EPS of $0.02, $0.09 worse than the analyst estimate of $0.11. Revenue for the quarter came in at $96.3 million versus the consensus estimate of $100.7 million.
Fusion-io (NYSE: FIO) 28.7% HIGHER; reported Q4 EPS of $0.09, versus $0.15 reported last year. Revenue for the quarter came in at $106.6 million, versus $71.7 million reported last year. Sees Q113 revs up modestly from Q4. Sees FY13 revenue growth in the range of 45 to 50%. For more, click here.
Roundys (NYSE: RNDY) 24.2% LOWER; reported Q2 EPS of $0.42, $0.01 worse than the analyst estimate of $0.43. Revenue for the quarter came in at $996.8 million versus the consensus estimate of $998.13 million. Sees FY2012 EPS of $1.10-$1.24, versus the consensus of $1.34. Downgraded by BB&T, Jefferies, and Credit Suisse.
Bottomline Technologies, Inc. (Nasdaq: EPAY) 20.8% HIGHER; reported Q4 EPS of $0.26, $0.04 better than the analyst estimate of $0.22. Revenue for the quarter came in at $61.4 million versus the consensus estimate of $59.75 million.
Imperva, Inc. (NYSE: IMPV) reported Q2 EPS of ($0.02), $0.03 better than the analyst estimate of ($0.05). Revenue for the quarter came in at $24.6 million versus the consensus estimate of $23.6 million. Sees Q3 2012 revenue of $24.6-$25 million, versus the consensus of $24.7 million. Imperva also sees FY2012 revenue of $99.5-$101.5 million, versus the consensus of $99.1 million.
Codexis, Inc. (Nasdaq: CDXS) 16.8% LOWER; reported Q2 EPS of ($0.15), $0.04 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $22.9 million versus the consensus estimate of $29.84 million.
Xinyuan Real Estate Co. (NYSE: XIN) 16.6% HIGHER; reported Q2 EPS of $0.94, $0.54 better than the analyst estimate of $0.40. Revenue for the quarter came in at $253.1 million versus the consensus estimate of $213.3 million. Sees Q3 2012 revenue of $225-$235 million, versus the consensus of $201.20 million. Sees FY2012 revenue of $825-$845 million, versus the consensus of $771.30 million. Yesterday, August 9, 2012, the Company acquired a parcel of land In Suzhou with a total GFA of approximately 128,000 square meters at a cost of RMB270 million(US$42.6 million).
eMagin Corp. (NYSE: EMAN) 15.3% HIGHER; reported Q2 EPS of $0.02, versus $0.01 reported last year. Revenue for the quarter came in at $8.6 million versus the consensus estimate of $7.4 million.
PharmAthene, Inc. (AMEX: PIP), 14.4% LOWER; received notification from the U.S. Food and Drug Administration (FDA) that its SparVax rPA anthrax vaccine program has been placed on clinical hold. The Agency indicated that the Company will receive a letter providing details of the basis for the clinical hold within 30 days. During this period, PharmAthene will continue to provide the agency with analytical data from its recently produced GMP lot of material. The clinical study, which was expected to begin by the end of this year, has not enrolled any subjects to date and accordingly, there have been no adverse events reported.
51job Inc (Nasdaq: JOBS) 13.1% HIGHER; reported Q2 EPS of $0.66, $0.09 better than the analyst estimate of $0.57. Revenue for the quarter came in at $56.7 million versus the consensus estimate of $55.4 million.
DG FastChannel, Inc. (Nasdaq: DGIT) 13.0% LOWER; reported Q2 EPS of $0.02, $0.09 worse than the analyst estimate of $0.11. Revenue for the quarter came in at $96.3 million versus the consensus estimate of $100.7 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ESSA Bancorp (ESSA) Tops Q2 EPS by 13c
- First Bancshares (FBMS) Tops Q1 EPS by 6c
- Celestica (CLS) Tops Q1 EPS by 14c
Create E-mail Alert Related Categories
Special ReportsRelated Entities
Credit Suisse, Deutsche Bank, Jefferies & Co, BB&T Capital Markets, Pacific Crest Securities, Morning Movers, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
